Topic:

R&D

Latest Headlines

Latest Headlines

Cabozantinib flops against prostate cancer, forcing big jobs cuts at Exelixis

Late on Monday evening Exelixis put out the word that its crucial late-stage study of cabozantinib flunked a comparison study with prednisone for castration-resistant prostate cancer, triggering a restructuring that will eliminate 70% of the jobs at the biotech.

Amazon's meeting with FDA starts the rumor mill turning

Amazon is the latest tech giant to consider expanding into healthcare, but details of the online retailer's plans are sketchy.

Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump

The development team from Sanofi and Regeneron journeyed to the ESC Congress in Barcelona this weekend to detail the impact their late-stage PCSK9 drug alirocumab has on bad cholesterol, drawing some high-profile attention for a batch of preliminary numbers suggesting a trend toward lower cardiovascular risks.

Novartis' LCZ696 kindles megablockbuster projections with impressive PhIII heart data

Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III trial. And today the pharma giant painted in the numbers, completing the late-stage picture for a closely watched therapy that has the potential to rival the most successful drug franchises now on the market.

FDA clears Glaxo Ebola vaccine for speedy human trials

GlaxoSmithKline's vaccine candidate for the deadly Ebola virus is ready to roll in human trials.

White House spotlights need for electrical implants to treat inflammatory and neurological diseases

President Obama highlighted a $78.9 million BRAIN Initiative project to improve service members' and veterans' health through the development of nano-scale electrical implants to modulate nerve signaling and record health biomarkers.

New antibody-drug conjugate research partnership announced

AB SCIEX and Dalton Pharma Services announced that they are joining forces on R&D of Antibody-Drug Conjugate analysis capabilities.

In India, surgeons use 3-D printed skull for practice

Plastic surgeons in India were able to convert CT scans of a three-year-old girl suffering with craniosynostosis into a physical replica using a 3-D printer. The realistic, life-size model was then used in practice runs of the surgery.

Vascular device drug delivery company surpasses VC goal

Advanced Catheter Therapies' venture capital funding round has been oversubscribed, reflecting investor interest in the company's Occlusion Perfusion Catheter for localized drug delivery in the peripheral vasculature.

Parkinson's play Civitas Therapeutics files for an $86M IPO

The S-1 prominently features Civitas' successful Phase IIb study for an inhaled formulation of levodopa, a "rescue" treatment for Parkinson's patients.